Research Article
Role of the Promoter Polymorphism IL-6 −174G/C in Dermatomyositis and Systemic Lupus Erythematosus
Table 5
Comparison between the genotypes and DM clinical parameters.
| Genotype | GG () | GC () | CC () | value |
| Muscle weakness | 12 (85.7%) | 11 (100.0%) | 5 (50.0%) | GG + GC—P = 0.012, G—P = 0.023 | Elevated muscle enzymes | 8 (57.1%) | 9 (81.8%) | 2 (20.0%) | GG + GC—P = 0.013, G—P = 0.054 | EMG findings | 7 (50.0%) | 8 (72.7%) | 5 (50.0%) |
NS* | Cutaneous disease | 11 (78.6%) | 9 (81.8%) | 7 (70.0%) | NS | Photosensitivity | 10 (71.4%) | 6 (54.5%) | 5 (50.0%) | NS | Immunological disease (anti-myositis-specific antibodies) | 3 (21.4%)
| 4 (36.4%)
| 2 (20.0%)
| NS
|
|
|
Not significant.
|